SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation)
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Item 5.07. Submission of Matters to a Vote of Security Holdings.
On May 26, 2021 at the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Bellerophon Therapeutics, Inc. (the “Company”), the stockholders approved the four proposals listed below. Of the 9,506,419 shares of common stock issued, outstanding and eligible to vote as of the record date of April 1, 2021, a quorum of 4,762,320 shares, or approximately 50.1% of the eligible shares, was present in person or represented by proxy. The final results for the votes regarding each proposal are set forth in the following tables.
(a) Election of Directors. The Company's stockholders elected the following nominees to serve on the Company's board of directors for a three-year term until the Company's 2024 annual meeting of stockholders and until each of their respective successors is duly elected and qualified, based on the following votes:
(b) Ratification of the Appointment of KPMG LLP as the Independent Registered Public Accountants of the Company for the Fiscal Year Ending December 31, 2021: The Company's stockholders approved the proposal based on the following votes:
(c) Approval by an Advisory Vote the Compensation of our Named Executive Officers: The Company's stockholders approved the proposal based on the following votes:
(d) The Frequency of Holding an Advisory Vote on the Compensation of our Named Executive Officers: The Company's stockholders approved the proposal based on the following votes:
Item 8.01. Other Events.
Bellerophon Therapeutics, Inc. (the “Company”) issued a press release on May 26, 2021 to announce the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors.
Item 9.01. Financial Statements and Exhibits.
Cover Page Interactive Data File (Formatted as Inline XBRL)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BELLEROPHON THERAPEUTICS, INC.
Date: May 26, 2021
/s/ Assaf Korner
Name: Assaf Korner